LB Pharmaceuticals names Joseph Miller as chief financial officer

LB Pharmaceuticals Inc (Nasdaq: LBRX) announced on September 3, 2026 that Joseph M. Miller has been appointed Chief Financial Officer, effective September 2, 2026¹. Miller, age 52, has more than two decades of experience across public and private biotech and pharmaceutical companies.¹

Miller most recently served as Chief Financial Officer of Aurinia Pharmaceuticals Inc., a public biopharmaceutical company focused on autoimmune disease therapies, holding the role from April 2020 to March 2026.¹ At Aurinia, he helped guide the company's transition from late-stage clinical development to the commercial launch of LUPKYNIS (voclosporin), described as the first FDA-approved oral therapy for active lupus nephritis.¹ He also oversaw revenue growth and profitability there, and the completion of an ex-U.S. licensing and collaboration agreement with Otsuka Pharmaceutical.¹

Before Aurinia, Miller was CFO, Principal Executive Officer, and Corporate Secretary at Avalo Therapeutics Inc., formerly known as Cerecor, Inc., a publicly traded biotech company.¹ Earlier roles included finance leadership positions at Sucampo Pharmaceuticals, QIAGEN, Eppendorf, and KPMG.

Under his employment agreement, Miller will receive an initial annual base salary of $530,000 and a target annual discretionary bonus equal to 40% of that base salary.¹ Subject to board approval, he will also receive an option to purchase 200,000 shares of common stock, vesting 25% after one year and monthly thereafter over four years.¹

CEO Heather Turner said in the release, the company is approaching its pivotal NOVA-2 clinical trial results while preparing for the potential launch of LB-102 in schizophrenia¹. LB Pharmaceuticals said LB-102 is its lead product candidate, which it believes could become the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.¹